Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 218

1.

Longitudinal associations between smoking cessation medications and alcohol consumption among smokers in the International Tobacco Control Four Country survey.

McKee SA, Young-Wolff KC, Harrison EL, Cummings KM, Borland R, Kahler CW, Fong GT, Hyland A.

Alcohol Clin Exp Res. 2013 May;37(5):804-10. doi: 10.1111/acer.12041. Epub 2012 Dec 14.

2.

Effectiveness of stop-smoking medications: findings from the International Tobacco Control (ITC) Four Country Survey.

Kasza KA, Hyland AJ, Borland R, McNeill AD, Bansal-Travers M, Fix BV, Hammond D, Fong GT, Cummings KM.

Addiction. 2013 Jan;108(1):193-202. doi: 10.1111/j.1360-0443.2012.04009.x. Epub 2012 Aug 14.

3.

Pharmacological interventions for smoking cessation: an overview and network meta-analysis.

Cahill K, Stevens S, Perera R, Lancaster T.

Cochrane Database Syst Rev. 2013 May 31;(5):CD009329. doi: 10.1002/14651858.CD009329.pub2. Review.

PMID:
23728690
4.

Usage patterns of stop smoking medications in Australia, Canada, the United Kingdom, and the United States: findings from the 2006-2008 International Tobacco Control (ITC) Four Country Survey.

Fix BV, Hyland A, Rivard C, McNeill A, Fong GT, Borland R, Hammond D, Cummings KM.

Int J Environ Res Public Health. 2011 Jan;8(1):222-33. doi: 10.3390/ijerph8010222. Epub 2011 Jan 20.

5.

Gender differences in medication use and cigarette smoking cessation: results from the International Tobacco Control Four Country Survey.

Smith PH, Kasza KA, Hyland A, Fong GT, Borland R, Brady K, Carpenter MJ, Hartwell K, Cummings KM, McKee SA.

Nicotine Tob Res. 2015 Apr;17(4):463-72. doi: 10.1093/ntr/ntu212.

6.

Nicotine receptor partial agonists for smoking cessation.

Cahill K, Stead LF, Lancaster T.

Cochrane Database Syst Rev. 2011 Feb 16;(2):CD006103. doi: 10.1002/14651858.CD006103.pub5. Review. Update in: Cochrane Database Syst Rev. 2012;4:CD006103.

PMID:
21328282
7.

Nicotine receptor partial agonists for smoking cessation.

Cahill K, Stead LF, Lancaster T.

Cochrane Database Syst Rev. 2010 Dec 8;(12):CD006103. doi: 10.1002/14651858.CD006103.pub4. Review. Update in: Cochrane Database Syst Rev. 2011;(2):CD006103.

PMID:
21154363
8.

Use of stop-smoking medications in the United States before and after the introduction of varenicline.

Kasza KA, Cummings KM, Carpenter MJ, Cornelius ME, Hyland AJ, Fong GT.

Addiction. 2015 Feb;110(2):346-55. doi: 10.1111/add.12778. Epub 2014 Nov 20.

9.

Varenicline treatment of concurrent alcohol and nicotine dependence in schizophrenia: a randomized, placebo-controlled pilot trial.

Meszaros ZS, Abdul-Malak Y, Dimmock JA, Wang D, Ajagbe TO, Batki SL.

J Clin Psychopharmacol. 2013 Apr;33(2):243-7. doi: 10.1097/JCP.0b013e3182870551.

PMID:
23422399
10.

An internet survey of use, opinions and preferences for smoking cessation medications: nicotine, varenicline, and bupropion.

Etter JF, Schneider NG.

Nicotine Tob Res. 2013 Jan;15(1):59-68. doi: 10.1093/ntr/nts084. Epub 2012 Apr 22.

PMID:
22529220
11.

Use of nicotine replacement therapy and stop-smoking medicines in a national sample of Aboriginal and Torres Strait Islander smokers and ex-smokers.

Thomas DP, Briggs VL, Couzos S, Panaretto KS, van der Sterren AE, Stevens M, Borland R.

Med J Aust. 2015 Jun 1;202(10):S78-84.

PMID:
26017263
12.

Varenicline versus transdermal nicotine patch: a 3-year follow-up in a smoking cessation clinic in Taiwan.

Hsueh KC, Hsueh SC, Chou MY, Pan LF, Tu MS, McEwen A, West R.

Psychopharmacology (Berl). 2014 Jul;231(14):2819-23. doi: 10.1007/s00213-014-3482-9. Epub 2014 Feb 13.

PMID:
24522334
13.

Comparison of the effectiveness of varenicline and combination nicotine replacement therapy for smoking cessation in clinical practice.

Brose LS, West R, Stapleton JA.

Mayo Clin Proc. 2013 Mar;88(3):226-33. doi: 10.1016/j.mayocp.2012.11.013. Epub 2013 Feb 27.

PMID:
23489449
14.

General practitioner prescribing of single and combination nicotine replacement therapy in the UK: a retrospective database study.

Johnson M, Anderson P, Lockhart I.

BMC Fam Pract. 2014 Mar 20;15:47. doi: 10.1186/1471-2296-15-47.

15.

Adherence to and reasons for premature discontinuation from stop-smoking medications: data from the ITC Four-Country Survey.

Balmford J, Borland R, Hammond D, Cummings KM.

Nicotine Tob Res. 2011 Feb;13(2):94-102. doi: 10.1093/ntr/ntq215. Epub 2010 Dec 8.

16.

Nicotine receptor partial agonists for smoking cessation.

Cahill K, Stead LF, Lancaster T.

Cochrane Database Syst Rev. 2008 Jul 16;(3):CD006103. doi: 10.1002/14651858.CD006103.pub3. Review. Update in: Cochrane Database Syst Rev. 2010;(12):CD006103.

PMID:
18646137
17.

Varenicline decreases alcohol consumption in heavy-drinking smokers.

Mitchell JM, Teague CH, Kayser AS, Bartlett SE, Fields HL.

Psychopharmacology (Berl). 2012 Oct;223(3):299-306. doi: 10.1007/s00213-012-2717-x. Epub 2012 May 1.

18.

Flexible and extended dosing of nicotine replacement therapy or varenicline in comparison to fixed dose nicotine replacement therapy for smoking cessation: rationale, methods and participant characteristics of the FLEX trial.

Tulloch H, Pipe A, Els C, Aitken D, Clyde M, Corran B, Reid RD.

Contemp Clin Trials. 2014 Jul;38(2):304-13. doi: 10.1016/j.cct.2014.05.011. Epub 2014 May 23.

PMID:
24861558
19.
20.

[Abstinence rates with varenicline compared to bupropion and nicotine replacement therapy for quitting smoking in primary care].

Sicras Mainar A, Navarro Artieda R, Díaz Cerezo S, Martí Sánchez B, Sanz De Burgoa V.

Aten Primaria. 2011 Sep;43(9):482-9. doi: 10.1016/j.aprim.2010.09.010. Epub 2011 Mar 5. Spanish.

Supplemental Content

Support Center